Literature DB >> 31788969

Muscle mass, strength, and physical performance predicting activities of daily living: a meta-analysis.

Daniel X M Wang1, Jessica Yao1, Yasar Zirek1, Esmee M Reijnierse1, Andrea B Maier1,2.   

Abstract

Background Activities of daily living (ADLs) and instrumental activities of daily living (IADLs) are essential for independent living and are predictors of morbidity and mortality in older populations. Older adults who are dependent in ADLs and IADLs are also more likely to have poor muscle measures defined as low muscle mass, muscle strength, and physical performance, which further limit their ability to perform activities. The aim of this systematic review and meta-analysis was to determine if muscle measures are predictive of ADL and IADL in older populations. Methods A systematic search was conducted using four databases (MEDLINE, EMBASE, Cochrane, and CINAHL) from date of inception to 7 June 2018. Longitudinal cohorts were included that reported baseline muscle measures defined by muscle mass, muscle strength, and physical performance in conjunction with prospective ADL or IADL in participants aged 65 years and older at follow-up. Meta-analyses were conducted using a random effect model. Results Of the 7760 articles screened, 83 articles were included for the systematic review and involved a total of 108 428 (54.8% female) participants with a follow-up duration ranging from 11 days to 25 years. Low muscle mass was positively associated with ADL dependency in 5/9 articles and 5/5 for IADL dependency. Low muscle strength was associated with ADL dependency in 22/34 articles and IADL dependency in 8/9 articles. Low physical performance was associated with ADL dependency in 37/49 articles and with IADL dependency in 9/11 articles. Forty-five articles were pooled into the meta-analyses, 36 reported ADL, 11 reported IADL, and 2 reported ADL and IADL as a composite outcome. Low muscle mass was associated with worsening ADL (pooled odds ratio (95% confidence interval) 3.19 (1.29-7.92)) and worsening IADL (1.28 (1.02-1.61)). Low handgrip strength was associated with both worsening ADL and IADL (1.51 (1.34-1.70); 1.59 (1.04-2.31) respectively). Low scores on the short physical performance battery and gait speed were associated with worsening ADL (3.49 (2.47-4.92); 2.33 (1.58-3.44) respectively) and IADL (3.09 (1.06-8.98); 1.93 (1.69-2.21) respectively). Low one leg balance (2.74 (1.31-5.72)), timed up and go (3.41 (1.86-6.28)), and chair stand test time (1.90 (1.63-2.21)) were associated with worsening ADL. Conclusions Muscle measures at baseline are predictors of future ADL and IADL dependence in the older adult population.
© 2019 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.

Entities:  

Keywords:  Activities of daily living; Aged; Handgrip strength; Muscle mass; Muscle strength; Physical performance

Mesh:

Year:  2019        PMID: 31788969      PMCID: PMC7015244          DOI: 10.1002/jcsm.12502

Source DB:  PubMed          Journal:  J Cachexia Sarcopenia Muscle        ISSN: 2190-5991            Impact factor:   12.910


Introduction

Dependence in activities of daily living (ADLs), the basic tasks required of an individual to maintain their independence at home, is associated with increased risk of morbidity and mortality.1, 2 Individuals that are dependent in ADL are also likely to be dependent in instrumental activities of daily living (IADLs), the tasks required of an individual to maintain their independence in the community.3, 4, 5 The prevalence of ADL and IADL disability for at least one activity is 34.6% and 53.5%, respectively, in adults aged 65 years and older,6 and this prevalence increases with age.7 Those with lower muscle measures, defined by muscle mass, muscle strength, and physical performance,8 are more likely to be dependent in ADL and/or IADL.9, 10, 11 The more difficult tasks are for an individual, the more effort and demand they require relative to their muscle's maximum capacity.12 Older adults that develop ADL dependence are less likely to recover function, stressing the need for strategies that can prevent or delay the onset of ADL dependence.13 Higher muscle strength is protective against declining below the threshold where dependence in ADL and IADL occurs.14 In community‐dwelling older adults, physical performance measured by gait speed has been shown to be a strong predictor of ADL disability.15, 16 Similarly, low muscle mass, muscle strength, and gait speed have all been associated with an impaired ability to perform ADL and IADL.17, 18 Currently, there are no systematic review and/or meta‐analyses that quantifies the association between muscle mass, muscle strength, and physical performance as predictors of ADL and IADL dependence. By determining which muscle measures are predictive of ADL and IADL dependence allows for the identification of individuals at high risk of decline as well as the development and implementation of strategies that can prevent or delay the onset of dependence. The aim of this systematic review and meta‐analysis was to determine if muscle mass, muscle strength, or physical performance are predictors of ADL and/or IADL at follow‐up in older populations.

Methods

Search strategy

This systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta‐analyses and registered with the PROSPERO International Prospective Register of Systematic Reviews (CRD42019125666).19 The following four electronic databases were screened for potential relevance from date of inception to 7 June 2018: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Cumulative Index of Nursing and Allied Health Literature. The search strategy was developed in consultation with a senior tertiary librarian from The University of Melbourne, with expertise in research and search strategies. The following terms were used in the search strategy: ‘muscle mass’, ‘fat free mass’, ‘lean mass’, ‘muscle loss’/atrophy, ‘muscle strength’, ‘physical performance’/mobility/fitness/endurance, ‘activities of daily living’, ‘functional decline’/disability, and aged/elderly/older. The full search strategy can be found in Supporting Information, Table .

Eligibility criteria

Inclusion criteria consisted of prospective longitudinal cohorts of older adults with a reported mean/median age of 65 years and older at follow‐up and reporting at least one of the following measurements: muscle mass, muscle strength, or physical performance in conjunction with a follow‐up outcome of ADL or IADL. Exclusion criteria included cross‐sectional and case–control studies; anthropometric measurements as measures of muscle mass such as body mass index, hip‐waist ratio, waist or calf circumference measurements, and skin‐fold thickness; populations that suffered from cancer, muscular dystrophy, genetically inherited diseases, and HIV/AIDS; cohorts that received an intervention other than usual care or placebo; and non‐English articles. Articles including participants of the same cohort more than once were excluded in a hierarchical manner: (i) if there was no statistical analysis conducted regarding odds ratio (OR), hazards ratio, or relative risk and lacking data to calculate the OR; (ii) if their primary research question was not exploring the association between muscle measures with ADL or IADL; or (iii) an article had a smaller sample size.

Article selection

Articles obtained through the search strategy had their title and abstract screened followed by full‐text screening for eligibility independently by two authors (D. W., Y. Z., or J. Y.) using Covidence (Covidence Systematic Review Software, Veritas Health Innovation, Melbourne, Australia). The decision made by authors was compared, and conflicts were settled by a third reviewer (E. M. R.).

Data extraction and quality assessment

Data extraction was performed by two authors (D. W., Y. Z., or J. Y.). The following data were extracted from included articles: author, year, study/cohort, setting, country/region, demographical information [sample size, age (mean/median), and sex (% female)], and follow‐up duration. Muscle mass, muscle strength, physical performance, ADL, and IADL were extracted based on the measurement method, unit, and cut‐offs applied in analyses. Effect sizes were extracted from text, tables, or figures if not described elsewhere. The quality of the included articles was assessed by a modified version of the Newcastle–Ottawa Scale (NOS) for cohort studies.20 Quality assessment was performed based on the following categories: selection, comparability, and outcome. Articles were deemed to be high quality with the following criteria: (i) the population was representative of the 65 years and older at follow‐up; (ii) in the case of a dichotomized sarcopenic cohort (low muscle mass, muscle strength, and physical performance), both cohorts were recruited from the same population; (iii) the technique used to measure muscle mass, muscle strength, or physical performance; (iv) the analysis was controlled for age and/or sex, as well as other factors; (v) ADL or IADL was measured with a validated method or a study designed questionnaire or survey; (vi) follow‐up duration was ≥3 months; and (vii) subjects were all followed up, accounted for or the number lost to follow‐up was unlikely to introduce bias (≤20%). The adapted version of the NOS can be found in Supporting Information, . Studies above the median score (7/7 and 8/8) were the cut‐off point for articles of high quality.21

Data synthesis and analysis

Effect sizes were extracted and reported where associations were made between baseline muscle measures and follow‐up ADL and/or IADL. Inclusion into the meta‐analysis required articles to report an OR, hazards ratio, relative risk, or if the article provided sufficient information to calculate an OR for the association between baseline muscle measures and follow‐up ADL and/or IADL. Forest plots were generated for the graphical representation of the meta‐analysis. A random effect model was adopted to account for differences between articles.22 Articles were presented in order from the shortest to longest follow‐up duration to determine if follow‐up duration impacts effect size, i.e. longer follow‐up duration showing greater effect size. Articles that reported sex‐stratified results or ADL and IADL were entered in the meta‐analysis separately. The least adjusted statistical model consisting of age and sex was used in the meta‐analysis, followed by the next least adjusted model then the unadjusted model. Heterogeneity was measured using the I‐squared (I 2) test. Low heterogeneity was defined as an I 2 ≤ 25%, moderate as 25–75%, and high as ≥75%.23 The P‐value for significance was set at <0.05, and the P‐value for a trend was set at 0.05 < P < 0.01. Meta‐analyses were performed separately according to the unit of gait speed, ADL, and IADL. The meta‐analysis was performed using Comprehensive Meta‐analysis (version 3.3; Biostat Inc., Englewood, NK).

Results

Figure 1 presents the Preferred Reporting Items for Systematic Reviews and Meta‐analyses flow diagram of selected articles. The four databases yielded 12 950 potential articles to which an additional 13 were added by snowballing. After removing duplicate articles, 7760 progressed to title and abstract screening. Of these, 7535 articles were excluded resulting in 225 articles for full‐text screening. Ultimately, 83 articles were included in the systematic review and 45 articles in the meta‐analysis.
Figure 1

Preferred Reporting Items for Systematic Reviews and Meta‐analyses flow chart for the study selection process.

Preferred Reporting Items for Systematic Reviews and Meta‐analyses flow chart for the study selection process.

Characteristics of included articles

Table 1 presents the study characteristics of included articles. The majority of the articles were conducted on community‐dwelling participants (n = 65/83). The mean or median age of the study ranged from 54 to 86 years at baseline. The number of participants in each study ranged from 41 to 8000 and included a total of 108 428 (54.8% female) participants. Follow‐up duration ranged from 11 days to 25 years. ADL was measured in 73 articles that examined physical motor tasks, 30 of which had developed an adapted questionnaire to assess the motor component of ADL (Supporting Information, Table ) and 21 articles using the Katz Index or a modified version. Of the articles reporting ADL, 63 articles used a dichotomous cut‐off reporting a worsening ADL score (≥1 points loss, i.e. more dependency) at follow‐up compared with using a continuous ADL score (n = 11). IADL was measured in 35 articles with the Lawton–Brody IADL scale being used in 14 articles, three of which were modified. A total of 26 articles included measures of both ADL and IADL.
Table 1

Characteristics of included studies and measured activities of daily living and instrumental activities of daily living

Study characteristicsParticipantsFUADLIADL
First author (year) [ref]Cohort nameSettingCountry N Age (years)F (%)MeasureCut‐offsMeasureCut‐offs
Abete (2017) 24 CDITA90781.3 ± 6.556.72 yKatz≥1 loss
Al snih (2004) 25 HEPESECDUSA249372.4 ± 6.2a 57.97 yM Katz≥1 loss
Albert (2015) 26 SITECDUSA37578.9 ± 5.868.92 yAMPSCont
Alexandre (2012) 27 SABECDBRA163468.6 ± 0.457.16 yM Katz≥1 loss
Amigues (2013) 28 EPIDOSCDFRA97579.9 ± 3.5100.04 yLB≥1 loss
Arnau (2016) 29 OPESP25281.7 ± 4.658.71 yBI≥10 lossM LB≥1 loss
Artaud (2015) 30 3CCDFRA381473.2 ± 4.660.911 yM Katz≥1 lossLB≥1 loss
Basic (2017) 31 IPAUS169381.9 ± 7.561.511 dM BI≥1 loss
Baumgartner (2004) 32 NMAPSCDUSA45172.7 ± 6.3a 61.98 yOwn Q≥1 loss
Beauchamp (2015) 33 Boston RISEPBUSA36076.6 ± 7.068.02 yLLFDI‐FCCont
Beloosesky (2009) 34 OPISR9381.2 ± 7.269.56 mOwn QCont
Bianchi (2015) 35 InCHIANTICDITA53877.1 ± 5.553.59 yLB≥1 loss
Broadwin (2001) 36 CDUSA105170.7a 60.34 yOwn Q≥1 loss
Carriere (2005) 37 EPIDOSCDFRA54579 (76–81)1007 yLB≥1 loss
Cesari (2015) 38 InCHIANTICDITA99173.9 ± 6.757.09 yKatz≥1 lossLBCont
Chan (2014) 39 ISCOPECDUSA76483 (79–87)68.21 yGARSContGARSCont
Chaudhry (2010) 40 CHSCDUSA588872.4a 57.67 yOwn Q≥1 loss
Chu (2006) 41 CDHKG141973.1 ± 6.249.51 yM BI≥1 lossLB≥1 loss
Cooper (2011) 42 LASACDNLD153270.0 ± 8.554.83 yOwn Q≥1 loss
Corsonello (2012) 43 PVCIPITA50680.1 ± 5.954.31 yM Katz≥1 loss
Costanzo (2018) 44 InCHIANTICDITA70973.4 ± 6.556.36 yKatz≥1 loss
Den Ouden (2013) 45 PROFIELCDNLD62562.3 ± 8.949.010 yM Katz≥1 loss
Denkinger (2010) 46 IRIECDDEU16182 (58–93)72.73 wBICont
Di Monaco (2015) 47 CDITA19380.0 ± 7.71006 mBI≥15 loss
Donoghue (2014) 48 TILDACDIRL181972.8 ± 6.152.62 yOwn Q≥1 lossOwn Q≥1 loss
Duchowny (2018) 49 HRSCDUSA846774.6 ± 7.0a 57.02 yOwn Q≥1 loss
Fantin (2007) 50 CDITA15971.4 ± 2.3a 61.06 yOwn Q≥1 lossOwn Q≥1 loss
Femia (1997) 51 OCTO ProjectCDSWE9586.8 ± 2.374.04 yOwn QContOwn QCont
Fujiwara (2016) 52 TMIG‐LISACDJPN98171.5 ± 5.258.18 yOwn Q≥1 loss
Giampaoli (1999) 53 FINECDITA14076.5 ± 3.4a 04 yWHO scale≥1 lossWHO scale≥1 loss
Gill (1996) 54 PSCDUSA77579.1 ± 5.0743 yM Katz≥1 loss
Gill (2009) 55 PEPCDUSA72278.4 ± 5.262.411 yOwn Q≥1 loss
Guralnik (2000) 56 EPESECDUSA24786 yOwn Q≥1 loss
Hansen (1999) 57 PBUSA7380.4 ± 7.066.01 mKatz≥1 lossM LB≥1 loss
Heiland (2016) 58 SNAC‐KCDSWE306073.7 ± 10.863.76 yOwn Q≥1 loss
Hirani (2015) 59 CHAMPCDAUS181977.3 ± 5.8a 05 yM Katz≥1 loss
Hirani (2017) 60 CHAMPCDAUS168576.9 ± 5.505 yM Katz≥1 lossLB≥1 loss
Hoeymans (1996) 61 Zitphen ElderlyCDNLD30375.8 ± 5.403 yM WHO≥1 lossM WHO≥1 loss
Hong (2016) 62 CDKOR800072.5 ± 5.559.43 yKIADL≥1 loss
Idland (2013) 63 CDNOR11379.4 ± 2.91009 yM A PADL‐H scale≥1 loss
Ishizaki (2000) 64 LISACDJPN58370.9 ± 4.955.93 yOwn Q≥1 lossTMIG IC≥1 loss
Janssen (2006) 65 CHSCDUSA369473.5a 53.28 yOwn Q≥1 loss
Jonkman (2018) 16 InCHIANTI, LASACDITA, NLD79867.5 ± 2.1a 53.89 yOwn Q≥1 lossOwn Q≥1 loss
Kempen (1998) 66 GLASCDNLD55772.4 ± 7.7a 74.72 yGARSCont
Kozicka (2016) 67 CDPOL4169.8 ± 9.041.51 yKatzContLBCont
Kwon (2012) 68 IPUSA20471.1 ± 5.357.81 yHAQ≥1 loss
Legrand (2014) 69 BFc80+CDBEL43184.4 ± 3.563.034 mOwn Q≥3 loss
Lopez‐Teros (2014) 70 CoyoacanCDMEX13375.5 ± 4.753.41 yOwn Q≥1 lossOwn Q≥1 loss
McGrath (2018) 71 HEPESECDUSA67281.7 ± 4.164.62 yM Katz≥1 lossOARS and RB≥1 loss
Minneci (2015) 72 ICARe DicomanoPB, HFITA56172.9 ± 7.1a 57.63 yOwn Q≥1 loss
Moen (2018) 73 PDNOR11586.0 ± 5.955.03 wNor BICont
Onder (2005) 74 WHASCDUSA88478.7 ± 8.01003 yOwn Q≥1 loss
Ostir (1998) 75 EPESECDUSA134273.353.02 yOwn Q≥1 loss
Peel (2014) 76 TCPAUS35179.0 ± 8.865.86 minterRAC HC≥1 loss
Pisters (2012) 77 IPNLD21666.1 ± 8.572.25 yWOMACCont
Purser (2005) 78 VAIPUSA138874 ± 6.02.01 yKatzContLBCont
Rajan (2012) 79 CNDSCDUSA531773.2 ± 6.461.08 yKatz≥1 loss
Rantanen (1999) 80 HPP, HAASCDUSA608954.0 ± 5.5025 yOwn Q≥1 loss
Rantanen (2002) 81 NORA75CDDNK, SWE, FIN56775+, NR60.05 yOwn Q≥1 loss
Rodriguez‐Pascual (2017) 82 PD, HFESP49785.2 ± 7.361.01 yKatz≥1 loss
Rothman (2008) 83 PEPCDUSA75478.4 ± 5.364.68 yOwn Q≥1 loss
Sakamoto (2016) 84 TLASCDJPN18880.2 ± 3.9a 65.42 yOwn Q≥1 loss
Sanchez‐Martinez (2016) 85 Penagrade cohortCDESP60777.0 ± 7.650.94 yOwn Q≥1 loss
Sanchez‐Rodrigeuz (2014) 86 IPESP9984.6 ± 6.661.63 mBICont
Sarkisian (2000) 87 SOFCDUSA663273.0 ± 4.91004 yOwn Q≥1 lossOwn Q≥1 loss
Sarkisian (2001) 88 SOFCDUSA8972.4 ± 4.5a 1004 yNHIS≥1 loss
Schoenenberg (2013) 89 IP, TAVICHE11983.4 ± 4.655.56 mKatz≥1 lossLB≥1 loss
Seidel (2011) 90 SHARECDEU684172 ± 6.052.52 yOwn Q≥1 loss
Shimada (2010) 91 E‐SAS projectCDJPN43679.2 ± 6.872.51 yTMIG IC≥1 loss
Shimada (2015) 92 OSHPECDJPN408171.7 ± 5.351.62 yLTIC≥1 loss
Shinkai (2000) 93 TMIG‐LISACDJPN748NRNR6 yOwn Q≥1 loss
Shinkai (2003) 94 TMIG‐LISACDJPN60173.0 ± 5.3654 yOwn Q≥1 lossTMIG IC≥1 loss
Sourdet (2012) 95 REAL.FRCD, ADFRA63277.8 ± 7.0a 72.22 yM Katz≥0.5 loss
Stenholm (2014) 96 InCHIANTICDITA72467.1 ± 15.0a 54.39 yOwn Q≥1 loss
Taekema (2010) 18 Leiden 85‐plusCDNLD555NR65.0NRGARS≥1 lossGARS≥1 loss
Takuhiro (2017) 97 Hizen‐OshimaCDJPN10469.3 ± 3.01009 yComposite≥3 loss
Tanimoto (2013) 98 CDJPN71673.2 ± 6.1a 65.82 yM Katz≥1 loss
Terhorst (2017) 99 OPUSA25678.9 ± 5.11006 mPASS≥1 lossPASS≥1 loss
Tinetti (2005) 100 PEP, PSCDUSA147178.8 ± 5.2a 70.83 yLB≥1 loss
Volpato (2011) 101 IPITA8777.4 ± 6.5a 49.03 mOwn QContM LBCont
Wennie Huang (2010) 102 CDUSA11080.3 ± 7.070.918 mNHIS≥1 loss
Zhang (2013) 103 InCHIANTICDITA56271.4 ± 5.747.93 yOwn Q≥1 lossOwn Q≥1 loss
Zoico (2007) 104 CDITA14571.7 ± 2.3a 58.62 yComposite≥1 loss

Cohort: 3C, Three City Study; BFc80+, BELFRAIL; Boston RISE, Boston Rehabilitative Impairment Study of the Elderly; CHAMP, The Concord Health and Ageing in Men Project; CHS, Cardiovascular Health Study; CNDS, Chicago Neighbourhood and Disability Study; Coyoacan, Mexica Study of Nutritional and Psychosocial Markers of Frailty among Community‐dwelling Elderly; EPESE, Established Populations for the Epidemiological Study for the Elderly; EPIDOS, epidemiology of osteoporosis; E‐SAS project, Elderly Status Assessment Set; FINE, Finland, Italy, Netherlands Elderly; GLAS, Groningen Longitudinal Ageing Study; HAAS, Honolulu Asia Aging Study; HEPESE, Hispanic Established Populations for the Epidemiological Study for the Elderly; HPP, Honolulu Heart Program; HRS, Health and Retirement Study; ICARe Dicomano, Insufficienza Cardiaca negi Anziani Residenti a Dicomano; InCHIANTI, Invecchiare in Chianti; ISCOPE, Integrated Systematic Care for Older People; LASA, Longitudinal Aging Study Amsterdam; NMAPS, New Mexico Aging Process Study; NORA75, Nordic Research on Aging 75 study; OSHPE, Obu Study of Health Promotion for the Elderly; PEP, Precipitating Events Project; PS, Project Safety; PVC, PharmacosurVeillance in the elderly Care; REAL.FR, Reseau sur la maladie Alzheimer Francais; SABE, Saude, Bem‐Estar e Envelhecimento; SITE, Sources of Independence in the Elderly; SHARE, The Survey of Health, Ageing and Retirement in Europe; SNAC‐K, Swedish National study on Aging and Care in Kungsholemn; SOF, Study of Osteoporotic Fractures; TILDA, The Irish Longitudinal Study of Ageing; LISA, Longitudinal Interdisciplinary Study on Aging; TLAS, Tosa Longitudinal Aging Study; TMIG‐LISA, Tokyo Metropolitan Institute of Gerontology Longitudinal Interdisciplinary Study on Ageing; VA, Department of Veterans Affairs; WHAS, Women's Health and Aging Study. Setting: AD, Alzheimer's disease; CD, community‐dwelling; OP, outpatients; IP, inpatients; TAVI, transcatheter aortic valve implantation; TCP, transitional care program; PB, population based; PD, post‐discharge; HF, heart failure. Country: AUS, Australia; BEL, Belgium; BRA, Brazil; CHE, Switzerland; DEU, Germany; DNK, Denmark; ESP, Spain; EU, Europe; FIN, Finland; FRA, France; HKG, Hong Kong; IRL, Ireland; ISR, Israel; ITA, Italy; JPN, Japan; KOR, Korea; MEX, Mexico; NLD, Netherlands; NOR, Norway; POL, Poland; SWE, Sweden; USA, United States. Age: presented as mean ± SD or median (range) or (IQR); range, percentage; —, not applicable or reported; F, female; FU, follow‐up duration; D, day(s); M, month(s); Y, year(s). ADL: —, not applicable or reported; BI, Barthel Index; Cont, continuous; GARS, Groningen Activities Restriction Scale; HAQ, Stanford Health Assessment Questionnaire; interRAC HC, interRAC Home Care; Nor BI, Norwegian Barthel Index; M A PADL‐H scale, modified Avlund Physical ADL‐H scale; M Katz, modified Katz Index; M BI, modified Barthel Index; M WHO, modified World Health Organization scale; LLFDI‐FC, Functional Component of the Late‐Life Function and Disability Instrument; LTCI, long‐term care insurance system; PASS, Performance Assessment of Self‐Care Skills; WHO, World Health Organization; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index. IADL: —, not applicable or reported; AMPS, assessment of motor and process skills; GARS, Groningen Activities Restriction Scale; KIADL, Korean IADL; LB, Lawton and Brody; M LB, modified Lawton and Brody; M WHO, modified WHO scale; NHIS, National Health Interview Survey; OARS, Older Americans Resources and Services; RB, Rosow‐Breslau scale; TMIG‐IC, Tokyo Metropolitan Institute of Gerontology Index of Competence.

Calculated mean ± SD or mean from information provided.

Characteristics of included studies and measured activities of daily living and instrumental activities of daily living Cohort: 3C, Three City Study; BFc80+, BELFRAIL; Boston RISE, Boston Rehabilitative Impairment Study of the Elderly; CHAMP, The Concord Health and Ageing in Men Project; CHS, Cardiovascular Health Study; CNDS, Chicago Neighbourhood and Disability Study; Coyoacan, Mexica Study of Nutritional and Psychosocial Markers of Frailty among Community‐dwelling Elderly; EPESE, Established Populations for the Epidemiological Study for the Elderly; EPIDOS, epidemiology of osteoporosis; E‐SAS project, Elderly Status Assessment Set; FINE, Finland, Italy, Netherlands Elderly; GLAS, Groningen Longitudinal Ageing Study; HAAS, Honolulu Asia Aging Study; HEPESE, Hispanic Established Populations for the Epidemiological Study for the Elderly; HPP, Honolulu Heart Program; HRS, Health and Retirement Study; ICARe Dicomano, Insufficienza Cardiaca negi Anziani Residenti a Dicomano; InCHIANTI, Invecchiare in Chianti; ISCOPE, Integrated Systematic Care for Older People; LASA, Longitudinal Aging Study Amsterdam; NMAPS, New Mexico Aging Process Study; NORA75, Nordic Research on Aging 75 study; OSHPE, Obu Study of Health Promotion for the Elderly; PEP, Precipitating Events Project; PS, Project Safety; PVC, PharmacosurVeillance in the elderly Care; REAL.FR, Reseau sur la maladie Alzheimer Francais; SABE, Saude, Bem‐Estar e Envelhecimento; SITE, Sources of Independence in the Elderly; SHARE, The Survey of Health, Ageing and Retirement in Europe; SNAC‐K, Swedish National study on Aging and Care in Kungsholemn; SOF, Study of Osteoporotic Fractures; TILDA, The Irish Longitudinal Study of Ageing; LISA, Longitudinal Interdisciplinary Study on Aging; TLAS, Tosa Longitudinal Aging Study; TMIG‐LISA, Tokyo Metropolitan Institute of Gerontology Longitudinal Interdisciplinary Study on Ageing; VA, Department of Veterans Affairs; WHAS, Women's Health and Aging Study. Setting: AD, Alzheimer's disease; CD, community‐dwelling; OP, outpatients; IP, inpatients; TAVI, transcatheter aortic valve implantation; TCP, transitional care program; PB, population based; PD, post‐discharge; HF, heart failure. Country: AUS, Australia; BEL, Belgium; BRA, Brazil; CHE, Switzerland; DEU, Germany; DNK, Denmark; ESP, Spain; EU, Europe; FIN, Finland; FRA, France; HKG, Hong Kong; IRL, Ireland; ISR, Israel; ITA, Italy; JPN, Japan; KOR, Korea; MEX, Mexico; NLD, Netherlands; NOR, Norway; POL, Poland; SWE, Sweden; USA, United States. Age: presented as mean ± SD or median (range) or (IQR); range, percentage; —, not applicable or reported; F, female; FU, follow‐up duration; D, day(s); M, month(s); Y, year(s). ADL: —, not applicable or reported; BI, Barthel Index; Cont, continuous; GARS, Groningen Activities Restriction Scale; HAQ, Stanford Health Assessment Questionnaire; interRAC HC, interRAC Home Care; Nor BI, Norwegian Barthel Index; M A PADL‐H scale, modified Avlund Physical ADL‐H scale; M Katz, modified Katz Index; M BI, modified Barthel Index; M WHO, modified World Health Organization scale; LLFDI‐FC, Functional Component of the Late‐Life Function and Disability Instrument; LTCI, long‐term care insurance system; PASS, Performance Assessment of Self‐Care Skills; WHO, World Health Organization; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index. IADL: —, not applicable or reported; AMPS, assessment of motor and process skills; GARS, Groningen Activities Restriction Scale; KIADL, Korean IADL; LB, Lawton and Brody; M LB, modified Lawton and Brody; M WHO, modified WHO scale; NHIS, National Health Interview Survey; OARS, Older Americans Resources and Services; RB, Rosow‐Breslau scale; TMIG‐IC, Tokyo Metropolitan Institute of Gerontology Index of Competence. Calculated mean ± SD or mean from information provided.

Qualitative analysis

Muscle mass was reported in 13 articles,28, 32, 35, 36, 37, 38, 50, 59, 60, 65, 86, 98, 104 six using dual‐energy X‐ray absorptiometry, five using bioelectrical impedance analysis, one using computed tomography, and one did not report the measurement method (Table 2). Low muscle mass was positively associated with worsening ADL in 5/9 articles and IADL in 5/5 at follow‐up.
Table 2

Muscle mass as predictor of activities of daily living or instrumental activities of daily living

First author (year) [ref] N ToolMeasureUnitsCut‐offsAMMA
Amigues (2013) 28 975DXASMIkg/m2 SD (NR)AY
Quartilea AN
975DXALMkgSD (NR)AN
Baumgartner (2004) 32 451DXASMIkg/m2 M: 7.26. F: 5.45AN
Bianchi (2015) 35 538BIASMIkg/m2 M: 8.87. F: 6.42AY
Broadwin (2001) 36 1051BIAFFM%Quintileb AN
Carriere (2005) 37 545LM/BM<0.54, 0.54–0.63, ≥0.63AN
Cesari (2015) 38 991CTMuscle densitymg/cm3 SD (M: 3.32. F: 3.60)AN
Fantin (2007) 50 159DXAFFMkgContinuousUN
Hirani (2015) 59 1819DXAALMkg<19.75AN
Hirani (2017) 60 1685DXAALM/BMI<0.789AY
Janssen (2006) 65 3694BIAMMkgQuartile (NR)AN
3694BIASMIkg/m2 M: <10.75. F: <6.75AY
Sanchez‐Rodrigeuz (2014) 86 99BIAFFMkgContinuousAN
99BIALBMkgContinuousAN
Tanimoto (2013) 98 716BIAAMIkg/m2 M: <7.0. F: <5.8UY
Zoico (2007) 104 145DXAAMIkg/m2 <7.6AN

Measure: —, not applicable or reported; ALM, appendicular lean mass; AMI, appendicular mass index; BIA, bioelectrical impedance analysis; BM, body mass; CT, computed tomography; DXA, dual‐energy X‐ray absorptiometry; FFM, fat free mass; LBM, lean body mass; LM, lean mass; MM, muscle mass; SMI, skeletal muscle index. Cut‐off: NR, not reported; SD, standard deviation. Expressed as either dichotomous, ranges for specific tertiles, quartiles, quintiles, or categories or per unit or score. AM, adjustment model denotes whether the model in the meta‐analysis was: A, adjusted; or U, unadjusted. MA, meta‐analysis; N, no; Y, yes.

≥6.72, 6.30–6.72, 5.82–6.30, <5.82.

M: 35.5–75.6, 75.7–78.0, 78.1–80.2, 80.3–82.8, 82.9–93.0. F: 45.6–67.0, 67.1–69.4, 69.5–71.8, 71.9–74.7, 74.8–88.0.

Muscle mass as predictor of activities of daily living or instrumental activities of daily living Measure: —, not applicable or reported; ALM, appendicular lean mass; AMI, appendicular mass index; BIA, bioelectrical impedance analysis; BM, body mass; CT, computed tomography; DXA, dual‐energy X‐ray absorptiometry; FFM, fat free mass; LBM, lean body mass; LM, lean mass; MM, muscle mass; SMI, skeletal muscle index. Cut‐off: NR, not reported; SD, standard deviation. Expressed as either dichotomous, ranges for specific tertiles, quartiles, quintiles, or categories or per unit or score. AM, adjustment model denotes whether the model in the meta‐analysis was: A, adjusted; or U, unadjusted. MA, meta‐analysis; N, no; Y, yes. ≥6.72, 6.30–6.72, 5.82–6.30, <5.82. M: 35.5–75.6, 75.7–78.0, 78.1–80.2, 80.3–82.8, 82.9–93.0. F: 45.6–67.0, 67.1–69.4, 69.5–71.8, 71.9–74.7, 74.8–88.0. Muscle strength as predictor of activities of daily living or instrumental activities of daily living Measure: —: not applicable or reported; AE, ankle extension; AF, arm flexion; BMI, body mass index; HGS, handgrip strength; KE, knee extension; QS, quadriceps strength; SS, shoulder strength; TE, trunk extension; TF, trunk flexion. Cut‐offs: NR, not reported; SD, standard deviation. Expressed as either dichotomous, ranges for specific tertiles, quartiles, quintiles, or categories or per unit or score. AM, adjustment model denotes whether the model in the meta‐analysis was: A, adjusted; or U, unadjusted. MA, meta‐analysis; N, no; Y, yes. M: <22.00, 21.01–30.00, 30.01–35.00, ≥35.01. F: <14.00, 14.01–18.20, 18.21–22.50, ≥22.51. M: ≤24: ≤29, 24.1–28: ≤30, >30: ≤32. F: ≤23: ≤17, 23.1–26: ≤17.3, 26.1–29: ≤21. M: ≤24: ≤29, 24.1–26: ≤30, 26.1–28: ≤30, >28: ≤32. F: ≤23: ≤17, 23.1–26: ≤17.3, 26.1–29: ≤18, >29: ≤21. M: <25, 25.0–29.9, 30.0–39.9, >40. F: <15, 15.0–19.9, 20.0–24.9, >25. M: <25.3, 25.4–33.2, >33.3. F: <15.0, 15.1–20.0, >20.1. <37.0, 37.0–42.0, >42.0. M: ≤24: ≤29, 24.1–26: ≤30, 26.1–28: ≤30, >28: ≤32. F: ≤23: ≤17, 23.1–26: ≤17.3, 26.1–29: ≤18, >29: ≤21. M: 65–74: <37, ≥75: <30. F: 65–74: <22, ≥75: <20. Muscle strength was investigated in 4118, 24, 25, 27, 28, 34, 35, 37, 38, 39, 40, 44, 45, 47, 49, 51, 53, 55, 59, 64, 67, 68, 69, 70, 71, 72, 73, 74, 77, 80, 81, 82, 83, 86, 87, 88, 90, 93, 94, 98, 102 articles as a predictor of ADL and IADL (Table 3). Handgrip strength was used as a measure of muscle strength in 40 articles, five using quadriceps or knee strength and each of the following were used in single articles: shoulder strength, ankle and torso flexion, and extension. Low muscle strength was positively associated with worsening ADL in 22/34 and IADL in 8/9 at follow‐up.
Table 3

Muscle strength as predictor of activities of daily living or instrumental activities of daily living

First author (year) [ref] N MeasureUnitsCut‐offsAMMA
Abete (2017) 24 907HGSNRDich (NR)AY
907SSNRDich (NR)AN
Al snih (2004) 25 2493HGSkgContinuousUY
Quartilea UY
Alexandre (2012) 27 1634HGSkgContinuousAY
Amigues (2013) 28 975HGSkPaSD (NR)AN
Beloosesky (2009) 34 93HGSkgContinuousUN
Bianchi (2015) 35 538HGSkgBMI specificb AN
Carriere (2005) 37 545HGSkPa<47AY
545QSN/cm<3.52, 3.52–4.95, ≥4.95AN
Cesari (2015) 38 991HGSkgSD (M: 10.11. F: 7.49)AN
991AEkgSD (M: 9.79. F: 8.35)AN
Chan (2014) 39 570HGSkgContinuousAN
570QSkgContinuousAN
Chaudhry (2010) 40 5888HGSkgLowest quintile for sex and BMI (NR)AY
Costanzo (2018) 44 709HGSLowest quintile for sex and BMI (NR)UY
Den Ouden (2013) 45 625HGSkgPer 10AN
625QSNmPer 10AN
Di Monaco (2015) 47 193HGSkgSD (5.7)AN
Duchowny (2018) 49 8467HGSkgWM: <35, BM: <40, WW: <22, BW: <31AY
Femia (1997) 51 95HGSkPaContinuousUN
Giampaoli (1999) 53 140HGSkPaContinuousAN
Gill (2009) 55 722HGSkgBMI specificc AY
Hirani (2015) 59 1819HGSkg<26AN
Ishizaki (2000) 64 468HGSkgContinuousAY
Kozicka (2016) 67 41HGSkgContinuousUN
Kwon (2012) 68 204HGSkgBMI specificd AN
Legrand (2014) 69 309HGSkgTertilee AY
Lopez‐Teros (2014) 70 133HGSkgContinuousAN
McGrath (2018) 71 672HGSkgContinuousAN
Minneci (2015) 72 453HGSkgContinuousAY
Moen (2018) 73 115HGSkgContinuousAN
Onder (2005) 74 458HGSkgSD (5.9)AN
Pisters (2012) 77 216KEN/kgSD (0.6)AN
Rantanen (1999) 80 6089HGSkgTertilef AN
Rantanen (2002) 81 553HGSNM: <392. F: <225UY
554AFNM: <274, <348. F: <159, <198AN
550KENM: <363, <449. F: <225, <287AN
546TENM: <542, <631. F: <271, <393AN
538TFNM: <472, <571. F: <231, <330AN
Rodriguez‐Pascual (2017) 82 277HGSkgLowest quintile for sex and BMI (NR)AY
Rothman (2008) 83 754HGSkgBMI specificg AY
Sanchez‐Rodrigeuz (2014) 86 99HGSkgContinuousUN
Sarkisian (2000) 87 6632HGSkgLowest Quintile (NR)AY
Sarkisian (2001) 88 89HGSkgDecile (NR)AN
Seidel (2011) 90 6670HGSkg<26UY
Shinkai (2000) 93 513HGSkgAge specifich UY
Shinkai (2003) 94 601HGSkgQuartile decreaseAY
Taekema (2010) 18 555HGSkgContinuousAN
Tanimoto (2013) 98 716HGSkgLowest quartile (NR)UN
Wennie Huang (2010) 102 65HGSkgContinuousAY

Measure: —: not applicable or reported; AE, ankle extension; AF, arm flexion; BMI, body mass index; HGS, handgrip strength; KE, knee extension; QS, quadriceps strength; SS, shoulder strength; TE, trunk extension; TF, trunk flexion. Cut‐offs: NR, not reported; SD, standard deviation. Expressed as either dichotomous, ranges for specific tertiles, quartiles, quintiles, or categories or per unit or score. AM, adjustment model denotes whether the model in the meta‐analysis was: A, adjusted; or U, unadjusted. MA, meta‐analysis; N, no; Y, yes.

M: <22.00, 21.01–30.00, 30.01–35.00, ≥35.01. F: <14.00, 14.01–18.20, 18.21–22.50, ≥22.51.

M: ≤24: ≤29, 24.1–28: ≤30, >30: ≤32. F: ≤23: ≤17, 23.1–26: ≤17.3, 26.1–29: ≤21.

M: ≤24: ≤29, 24.1–26: ≤30, 26.1–28: ≤30, >28: ≤32. F: ≤23: ≤17, 23.1–26: ≤17.3, 26.1–29: ≤18, >29: ≤21.

M: <25, 25.0–29.9, 30.0–39.9, >40. F: <15, 15.0–19.9, 20.0–24.9, >25.

M: <25.3, 25.4–33.2, >33.3. F: <15.0, 15.1–20.0, >20.1.

<37.0, 37.0–42.0, >42.0.

M: ≤24: ≤29, 24.1–26: ≤30, 26.1–28: ≤30, >28: ≤32. F: ≤23: ≤17, 23.1–26: ≤17.3, 26.1–29: ≤18, >29: ≤21.

M: 65–74: <37, ≥75: <30. F: 65–74: <22, ≥75: <20.

A total of 62 articles16, 26, 27, 28, 29, 30, 31, 33, 35, 37, 38, 40, 41, 42, 43, 44, 45, 46, 48, 49, 52, 54, 55, 56, 57, 58, 59, 61, 62, 63, 66, 68, 69, 70, 71, 72, 73, 74, 75, 76, 78, 79, 82, 83, 84, 85, 87, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103 reported physical performance as a predictor of ADL and IADL (Table 4). Gait speed was the most reported measure, with a total of 37 articles, followed by the composite test short physical performance battery (SPPB), which was reported in 14 articles. Other measures of physical performance included a variety of balance (n = 15), chair stand (n = 10), timed up and go (n = 8), and functional reach tests (n = 2) as well as tests that involve multiple assessments (n = 3). Poor physical performance was positively associated with worsening ADL in 37/49 articles and IADL in 9/11 at follow‐up: SPPB (10/13, 2/2), gait speed (27/33, 7/8), one leg balance (3/4, 0/0), and chair stand test (4/9, 0/1).
Table 4

Physical performance as predictor of activities of daily living or instrumental activities of daily living

First author (year) [ref] N MeasureUnitsCut‐offsAMMA
Albert (2015) 26 347Gaitm/sQuartilea AN
Alexandre (2012) 27 1634OLBsContinuousAN
1634CSTsContinuousAN
Amigues (2013) 28 975Gaitm/sSD (0.22)AN
974BalancesTertileb AN
Arnau (2016) 29 252SPPBpoints<7UY
Artaud (2015) 30 3814Fast Gaitm/sSD (0.22)AN
3814Change in FGm/sSD (0.013)AN
Basic (2017) 31 1693TUGsContinuousUN
Beauchamp (2015) 33 430SPPBpointsContinuousUN
430Gaitm/sContinuous (0.1)UN
428400 m walkminContinuousUN
413Stair climbwattsContinuousUN
Bianchi (2015) 35 538Gaitm/s<0.8AN
Carriere (2005) 37 545Gaitm/s<0.78AY
545Standing balanceTertilec AN
545Dynamic balanceCat (3)AN
545CSTs<13 sAY
545Foot tappingTertileAN
Cesari (2015) 38 991Gaitm/sSD (M: 0.24. F: 0.23)AY
Chaudhry (2010) 40 5888Gaitm/sLowest quintile for sex and height (NR)AY
Chu (2006) 41 1338Gaitm/s<0.65 m/sAY
Cooper (2011) 42 1425Timed walk testContinuousAN
1425Tandem standAN
1425Cardigan testsAN
1425CSTsAN
Corsonello (2012) 43 506SPPBpointsContinuousAY
<9UY
Costanzo (2018) 44 709Gaitm/sLowest quintile for sex and height (NR)UY
709BalancesLowest quintile for sex and height (NR)UN
Den Ouden (2013) 45 625SPPBpointsContinuousAY
Denkinger (2010) 46 161Change in gaitm/sContinuousAN
Donoghue (2014) 48 1391Gaitm/sContinuous (0.1)UN
1391TUGsContinuousUN
Duchowny (2018) 49 8467Gaitm/s<0.8AY
Fujiwara (2016) 52 981Gaitm/sTertile (NR)AY
Gill (1996) 54 775Own testQuartile (25%)UN
Gill (2009) 55 722SPPBpointsContinuousAY
722RGTs≤10UN
722Gait and balancepointsContinuousUN
722CSTsDich (NR)UY
722ChairDichUN
722Manual dexteritysQuartiled UN
722GMCsQuartilee UN
Guralnik (2000) 56 2542SPPBpoints<10UY
Hansen (1999) 57 73TUGsTertilef UN
73Tinetti balancepointsTertileg UN
Heiland (2016) 58 1971Gaitm/s<0.8AY
1971OLBs<5AY
Hirani (2015) 59 1819Gaitm/s≤0.8AN
Hoeymans (1996) 61 303Gaitm/s<0.73UN
303CSTs≤17.2UN
Hong (2016) 62 8000Gaitm/s<0.6AY
Idland (2013) 63 113Gaitm/sCont (1)AY
113FRTcmCont (1)AN
113Step climb testcmPer 10AN
Jonkman (2018) 16 798Gaitm/sDich (NR)AN
798Tandem stands<10 sAN
Kempen (1998) 66 557Walk turn walksContAN
557CSTsContAN
557CSTsContAN
557JacketsContAN
Kwon (2012) 68 204Gaitm/sQuartileh AN
204BalancesFT10, FT1‐9, ST10, StS10AN
204CSTsQuartilei AN
Legrand (2014) 69 308SPPBpointsM: <10. F: <8UY
Lopez‐Teros (2014) [54]133Gaitm/sContinuous (1)AY
McGrath (2018) 71 672Gaitm/sLowest quintile for sex and height (NR)AY
Minneci (2015) 72 453Gaitm/sContinuous (1)AY
453SPPBpointsContinuousAY
4536MWTmContinuousAN
Moen (2018) 73 75TUGsContinuousAN
Onder (2005) 74 458BalancesSD (10.2)AN
458CSTsSD (8.4)AN
458Gaitm/sSD (0.31)AY
458LE compSD (0.69)AN
458BlousesSD (72)AN
458PurduesSD (10.5)AN
458UE compSD (0.49)AN
Ostir (1998) 75 1342SPPBpoints<9UY
1328Gaitm/s<0.8UY
1342CSTs<10.9UY
1006BalancesFT10, FT2‐10, StS10UN
Peel (2014) 76 280Gaitm/sContinuous (0.1)AY
Purser (2005) 78 1388Gaitm/sContinuous (0.1)AN
1388Change in gaitm/sContinuous (0.1)AN
Rajan (2012) 79 5317M SPPBpointsContinuousAY
Rodriguez‐Pascual (2017) 82 218Gaitm/sLowest quintile for sex (NR)AY
Rothman (2008) 83 Gaitm/s<0.3AN
Sakamoto (2016) 84 188TUGs<15 sAY
188FRTcm<20AN
Sanchez‐Martinez (2016) 85 607SPPBpoints<8AN
607Gaitm/s<0.8AN
Sarkisian (2000) 87 6632Gaitm/sLowest quintile (NR)AN
Schoenenberg (2013) 89 119TUGs<20 sUY
Seidel (2011) 90 1804Gaitm/s<0.4UY
Shimada (2010) 91 436TUGs<12AY
Shimada (2015) 92 4081Gait<1.0AN
Shinkai (2000) 93 513UWSm/sTertilej UY
513MWSm/sAge and sex specific quartilesk AN
513OLBsTertilel UY
Shinkai (2003) 94 601Gaitm/sQuartile lowerAN
601Fast gaitm/sQuartile lowerAN
601OLBsQuartile lowerAN
Sourdet (2012) 95 583OLBs<5AN
Stenholm (2014) 96 727Gaitm/sContinuous (0.1)AY
727SPPBpointsContinuousUY
Takuhiro (2017) 97 104RWSm/sSD (0.24)AY
Tanimoto (2013) 98 716Gaitm/sLowest quartile (NR)UN
Terhorst (2017) 99 256BalanceNRUN
256Forward reachNRUN
Tinetti (2005) 100 1042CSTsTertilem UN
Volpato (2011) 101 74SPPBpoints<8UY
Wennie Huang (2010) 102 65SPPBpointsContinuousAY
65Gaitm/sContinuous (1)AY
65BBSpointsContinuousAN
65TUGsContinuousAN
Zhang (2013) 103 504CSTs<11.2AY

Physical Performance: —, not applicable or reported; 6MWT, 6 min walk test; BBS, Berg Balance Scale; CST, chair stand test; OLB, one leg balance; FRT, functional reach test; FT, full tandem; MWS, maximum walking speed; POMA, performance oriented mobility assessment; PPT, physical performance test; RGT, rapid gait test; RWS, regular walking speed; SPPB, short physical performance battery; ST, semi tandem; StS, side to side; TUG, timed up and go; UWS, usual walking speed; WS, walking speed. Cut‐offs: NR, not reported; SD, standard deviation. Expressed as either dichotomous, ranges for specific tertiles, quartiles, quintiles, or categories or per unit or score unless otherwise stated in brackets. AM, adjustment model denotes whether the model in the meta‐analysis was: A, adjusted; or U, unadjusted. MA, meta‐analysis; N, no; Y, yes.

≥1, 0.74–0.99, 0.57–0.73, <0.57.

<2, 3–9, ≥10.

Full tandem, semi tandem, side to side.

<21.8, 21.8–24.3, 24.4–27.5, ≥27.6.

<8.8, 8.8–10.3, 10.4–12.4, ≥12.5.

<20, 20–40, ≥40.

15–27, 28–38, 39–41.

M: >4.5, 4.0–4.5, 3.0–3.9, <3. F: >5, 4.0–5.0, 3.0–3.9, <3.

M: >20, 17.0–19.0, 11–16.9. F: >21, 18.0–20.9, 12.0–17.9, <12.

M: ≤1.08, ≥75: ≥0.82. F: ≤0.9, ≥75: ≤0.69.

M: 65–74: ≤1.81, 1.82–2.10, 2.11–2.36, ≥2.37. ≥75: ≤1.34, 1.35–1.64, 1.65–1.99, ≥2.00. F: 65–75: ≤1.45, 1.46–1.70, 1.71–1.98, ≥1.97. ≥75: ≤1.08, 1.09–1.34, 1.35–1.62, ≤1.63.

M: ≤18, ≥75: ≤5. F: ≤7, ≥75: ≤16.

<9, 9–14, >14.

Physical performance as predictor of activities of daily living or instrumental activities of daily living Physical Performance: —, not applicable or reported; 6MWT, 6 min walk test; BBS, Berg Balance Scale; CST, chair stand test; OLB, one leg balance; FRT, functional reach test; FT, full tandem; MWS, maximum walking speed; POMA, performance oriented mobility assessment; PPT, physical performance test; RGT, rapid gait test; RWS, regular walking speed; SPPB, short physical performance battery; ST, semi tandem; StS, side to side; TUG, timed up and go; UWS, usual walking speed; WS, walking speed. Cut‐offs: NR, not reported; SD, standard deviation. Expressed as either dichotomous, ranges for specific tertiles, quartiles, quintiles, or categories or per unit or score unless otherwise stated in brackets. AM, adjustment model denotes whether the model in the meta‐analysis was: A, adjusted; or U, unadjusted. MA, meta‐analysis; N, no; Y, yes. ≥1, 0.74–0.99, 0.57–0.73, <0.57. <2, 3–9, ≥10. Full tandem, semi tandem, side to side. <21.8, 21.8–24.3, 24.4–27.5, ≥27.6. <8.8, 8.8–10.3, 10.4–12.4, ≥12.5. <20, 20–40, ≥40. 15–27, 28–38, 39–41. M: >4.5, 4.0–4.5, 3.0–3.9, <3. F: >5, 4.0–5.0, 3.0–3.9, <3. M: >20, 17.0–19.0, 11–16.9. F: >21, 18.0–20.9, 12.0–17.9, <12. M: ≤1.08, ≥75: ≥0.82. F: ≤0.9, ≥75: ≤0.69. M: 65–74: ≤1.81, 1.82–2.10, 2.11–2.36, ≥2.37. ≥75: ≤1.34, 1.35–1.64, 1.65–1.99, ≥2.00. F: 65–75: ≤1.45, 1.46–1.70, 1.71–1.98, ≥1.97. ≥75: ≤1.08, 1.09–1.34, 1.35–1.62, ≤1.63. M: ≤18, ≥75: ≤5. F: ≤7, ≥75: ≤16. <9, 9–14, >14.

Quality assessment

A complete breakdown of the NOS can be found in Table 5. The majority of the articles were of high quality (46/83).
Table 5

Quality assessment of included studies using a modified Newcastle–Ottawa Scale (NOS)

First author (year) [ref]SelectionCompOutcomeTotal score
Q1Q2a Q3Q1Q1Q2Q3
Abete (2017) 24 1111116/7
Al snih (2004) 25 1121117/7
Albert (2015) 26 1101115/7
Alexandre (2012) 27 1101115/7
Amigues (2013) 28 11121118/8
Arnau (2016) 29 1121117/7
Artaud (2015) 30 1121117/7
Basic (2017) 31 1101003/7
Baumgartner (2004) 32 11121118/8
Beauchamp (2015) 33 1101104/7
Beloosesky (2009) 34 0101114/7
Bianchi (2015) 35 11121118/8
Broadwin (2001) 36 1121117/7
Carriere (2005) 37 1121117/7
Cesari (2015) 38 11121118/8
Chan (2014) 39 1111116/7
Chaudhry (2010) 40 1121117/7
Chu (2006) 41 1121117/7
Cooper (2011) 42 1121117/7
Corsonello (2012) 43 0121116/7
Costanzo (2018) 44 1101115/7
Den Ouden (2013) 45 1121117/7
Denkinger (2010) 46 1121016/7
Di Monaco (2015) 47 1121117/7
Donoghue (2014) 48 1101115/7
Duchowny (2018) 49 1121117/7
Fantin (2007) 50 1101115/7
Femia (1997) 51 1101115/7
Fujiwara (2016) 52 1121117/7
Giampaoli (1999) 53 1121117/7
Gill (1996) 54 1121117/7
Gill (2009) 55 1121117/7
Guralnik (2000) 56 1121117/7
Hansen (1999) 57 1101014/7
Heiland (2016) 58 1121117/7
Hirani (2015) 59 11121118/8
Hirani (2017) 60 11121118/8
Hoeymans (1996) 61 1111116/7
Hong (2016) 62 1121117/7
Idland (2013) 63 1121117/7
Ishizaki (2000) 64 1121117/7
Janssen (2006) 65 11121118/8
Jonkman (2018) 16 1121117/7
Kempen (1998) 66 1111116/7
Kozicka (2016) 67 1101104/7
Kwon (2012) 68 0121116/7
Legrand (2014) 69 1121117/7
Lopez‐Teros (2014) 70 1121117/7
McGrath (2018) 71 1121117/7
Minneci (2015) 72 0121116/7
Moen (2018) 73 1121016/7
Onder (2005) 74 1111116/7
Ostir (1998) 75 1121106/7
Peel (2014) 76 0111104/7
Pisters (2012) 77 0121116/7
Purser (2005) 78 0121116/7
Rajan (2012) 79 1121117/7
Rantanen (1999) 80 1121117/7
Rantanen (2002) 81 1111116/7
Rodriguez‐Pascual (2017) 82 0111115/7
Rothman (2008) 83 1121117/7
Sakamoto (2016) 84 1121117/7
Sanchez‐Martinez (2016) 85 1121117/7
Sanchez‐Rodrigeuz (2014) 86 01101115/8
Sarkisian (2000) 87 1121117/7
Sarkisian (2001) 88 1121117/7
Schoenenberg (2013) 89 0101114/7
Seidel (2011) 90 1121117/7
Shimada (2010) 91 1121117/7
Shimada (2015) 92 1121106/7
Shinkai (2000) 93 1121117/7
Shinkai (2003) 94 1121117/7
Sourdet (2012) 95 0121116/7
Stenholm (2014) 96 1121117/7
Taekema (2010) 18 1111116/7
Takuhiro (2017) 97 1101115/7
Tanimoto (2013) 98 11121118/8
Terhorst (2017) 99 1101115/7
Tinetti (2005) 100 1101115/7
Volpato (2011) 101 0101114/7
Wennie Huang (2010) 102 1121106/7
Zhang (2013) 103 1121117/7
Zoico (2007) 104 1121106/7

Comp, comparability.

Only applied to studies that dichotomized sarcopenic cohorts.

Quality assessment of included studies using a modified Newcastle–Ottawa Scale (NOS) Comp, comparability. Only applied to studies that dichotomized sarcopenic cohorts.

Meta‐analysis

Muscle mass

Two articles60, 98 evaluating muscle mass (low vs. high) and its association with ADL were included in the meta‐analysis. Low muscle mass was associated with worsening ADL [OR = 3.19, 95% confidence interval (CI): 1.29–7.92, I 2 = 68.8]. Four articles28, 35, 60, 65 were pooled into a meta‐analysis exploring the effect of muscle mass (low vs. high), which favoured worsening IADL (OR = 1.28, 95% CI: 1.02–1.61, I 2 = 75.8) (Figure 2).
Figure 2

Forest plot showing the association between baseline muscle mass (low vs. high) with activity of daily living (ADL) and instrumental activity of daily living (IADL) at follow‐up. Heterogeneity (I 2): ADL = 68.8. IADL = 75.8. M, male; F, female. Articles that reported both ADL and IADL were denoted a and b.

Forest plot showing the association between baseline muscle mass (low vs. high) with activity of daily living (ADL) and instrumental activity of daily living (IADL) at follow‐up. Heterogeneity (I 2): ADL = 68.8. IADL = 75.8. M, male; F, female. Articles that reported both ADL and IADL were denoted a and b.

Muscle strength

Six articles25, 27, 64, 72, 102, 105 evaluating the association between handgrip strength (per 1 kg lower) and ADL were pooled, favoured worsening ADL (OR = 1.09, 95% CI: 1.05–1.13, I 2 = 87.5) (Figure 3A). Ten articles24, 25, 40, 44, 49, 69, 81, 82, 83, 93 were pooled into meta‐analysis demonstrating the association between low vs. high handgrip strength with ADL (Figure 3B). The pooled result again favoured worsening ADL (OR = 1.51, 95% CI: 1.34–1.70, I 2 = 50.0). Four articles37, 87, 90, 93 were pooled measuring handgrip strength (low vs. high) and IADL favouring worsening ADL (OR = 1.59, 95% CI: 1.04–2.41, I 2 = 94.7) (Figure 3B).
Figure 3

Forest plot showing the association between baseline handgrip strength with activity of daily living (ADL) and instrumental activity of daily living (IADL) at follow‐up. (A) Handgrip strength (per 1 kg lower), heterogeneity (I 2) = 72.8. (B) Handgrip strength (low vs. high), heterogeneity (I 2): ADL = 50.0. IADL: 94.7. M, male; F, female.

Forest plot showing the association between baseline handgrip strength with activity of daily living (ADL) and instrumental activity of daily living (IADL) at follow‐up. (A) Handgrip strength (per 1 kg lower), heterogeneity (I 2) = 72.8. (B) Handgrip strength (low vs. high), heterogeneity (I 2): ADL = 50.0. IADL: 94.7. M, male; F, female.

Physical performance

Seven articles43, 45, 55, 72, 79, 96, 102 evaluating the association between SPPB and ADL were pooled, which demonstrated that a lower SPPB score (per one point) is associated with worsening ADL (OR = 1.12, 95% CI: 1.07–1.18, I 2 = 91.8) (Figure 4A). Four articles43, 56, 69, 75 were pooled exploring the association between SPPB (low vs. high) and ADL (Figure 4B). The pooled effect favoured worsening ADL (OR = 3.49, 95% CI: 2.47–4.92, I 2 = 63.3). Two articles29, 101 combined ADL and IADL and showed that SPPB score (low vs. high) favoured a worsening of the combined ADL and IADL measure (OR = 3.09, 95% CI: 1.06–8.98, I 2 = 57.6) (Figure 4B).
Figure 4

Forest plot showing the association between short physical performance battery (SPPB) with activity of daily living (ADL) and/or instrumental activity of daily living (IADL) at follow‐up. (A) SPPB (per 1 point lower), heterogeneity (I 2) = 91.8. (B) SPPB (low vs. high), heterogeneity (I 2): ADL = 63.3. IADL = 57.6.

Forest plot showing the association between short physical performance battery (SPPB) with activity of daily living (ADL) and/or instrumental activity of daily living (IADL) at follow‐up. (A) SPPB (per 1 point lower), heterogeneity (I 2) = 91.8. (B) SPPB (low vs. high), heterogeneity (I 2): ADL = 63.3. IADL = 57.6. Seven articles were pooled in a meta‐analysis demonstrating the association of gait speed (per unit increase) with ADL (Figure 5A). After subgrouping for a lower unit (per 0.1 m/s, per 1 m/s and per SD) in gait speed, a lower gait speed of 0.1 m/s76, 96 was not associated with worsening ADL (OR = 1.64, 95% CI: 0.80–3.38, I 2 = 85.0) while a lower gait speed of 1.0 m/s63, 72, 102 and 1 SD38, 74 was associated with worsening ADL (OR = 4.40, 95% CI: 1.34–14.48, I 2 = 52.1; OR = 1.85, 95% CI: 1.44–2.36, I 2 = 62.8). Six articles41, 49, 52, 58, 75, 93 pooling gait speed (low vs. high) with ADL favoured worsening in ADL (OR = 2.33, 95% CI: 1.58–3.44, I 2 = 94.2) (Figure 5B). Four articles37, 41, 62, 90 evaluating the association between gait speed (low vs. high) with IADL demonstrated worsening in IADL (OR = 1.93, 95% CI: 1.69–2.21, I 2 = 0.0) (Figure 5B). Five articles40, 44, 71, 82, 87 were pooled comparing the lowest quintile for gait speed with the upper four quintiles with ADL demonstrated an association in worsening ADL (OR = 3.08, 95% CI: 2.13–4.46, I 2 = 75.7) (Figure 5C).
Figure 5

Forest plot showing the association between gait speed with activity of daily living (ADL) and instrumental activity of daily living (IADL) at follow‐up. (A) Gait (per unit lower), heterogeneity (I 2): 0.1 m/s = 85. 1.0 m/s = 52.1. SD = 62.8. (B) Gait (low vs. high), heterogeneity (I 2): ADL = 94.2. IADL = 0.0. (C) Gait (lowest quintile vs. upper four quintiles), heterogeneity (I 2) = 75.7.

Forest plot showing the association between gait speed with activity of daily living (ADL) and instrumental activity of daily living (IADL) at follow‐up. (A) Gait (per unit lower), heterogeneity (I 2): 0.1 m/s = 85. 1.0 m/s = 52.1. SD = 62.8. (B) Gait (low vs. high), heterogeneity (I 2): ADL = 94.2. IADL = 0.0. (C) Gait (lowest quintile vs. upper four quintiles), heterogeneity (I 2) = 75.7. Three articles58, 93, 95 were pooled demonstrating a strong association between one leg balance (low vs. high) and a decline in ADL (OR = 2.74, 95% CI: 1.31–5.72, I 2 = 88.5) (Figure 6A). Two articles84, 89 reported timed up and go (slow vs. fast) with ADL (Figure 6B). Slow timed up and go favoured worsening in ADL (OR = 3.41, 95% CI: 1.86–6.28, I 2 = 41.6). Three articles55, 75, 103 explored the effect of chair stand test time (slow vs. fast) with ADL (Figure 6B). Slow chair stand test favoured worsening in ADL (OR = 1.90, 95% CI: 1.63–2.21, I 2 = 0.0). Two articles37, 103 were pooled exploring the effect of chair stand test time (slow vs. fast) was not associated with worsening IADL (OR = 2.10, 95% CI: 0.80–5.48, I 2 = 74.8) (Figure 6C).
Figure 6

Forest plot showing the association between other physical performance measures with activity of daily living (ADL) at follow‐up. (A) One leg balance time (low vs. high), heterogeneity (I 2) = 88.5. (B) Timed up and go (slow vs. fast), heterogeneity (I 2) = 41.6. (C) Chair stand test time (slow vs. fast), heterogeneity (I 2): ADL = 0.0. Instrumental activity of daily living (IADL) = 74.8. Articles that reported both ADL and IADL were denoted a and b.

Forest plot showing the association between other physical performance measures with activity of daily living (ADL) at follow‐up. (A) One leg balance time (low vs. high), heterogeneity (I 2) = 88.5. (B) Timed up and go (slow vs. fast), heterogeneity (I 2) = 41.6. (C) Chair stand test time (slow vs. fast), heterogeneity (I 2): ADL = 0.0. Instrumental activity of daily living (IADL) = 74.8. Articles that reported both ADL and IADL were denoted a and b. All meta‐analyses were ordered by study follow‐up duration from shortest to longest. No pattern was present based on follow‐up duration in all meta‐analyses.

Discussion

Muscle mass was associated with the development of IADL dependence. Muscle strength and physical performance were associated with the development of ADL and IADL dependence at follow‐up in older adults.

Muscle mass

Surprisingly, muscle mass was associated with the development of new IADL dependence, but not ADL dependence at follow‐up in this meta‐analysis. While the association between muscle mass and ADL was not statistically significant, perhaps because of only two studies being included, a trend suggested that it was a clinically significant predictor of worsening ADL. The Concord Health and Ageing in Men Project reported that low muscle mass and sarcopenic obesity were significantly associated with worsening ADL and IADL.60 Additionally, a prospective study reported that low fat free mass was associated with functional disability.36 It has been previously hypothesized that muscle mass plays an important role in the loss of ADL with increasing age 106. Loss of muscle mass could be explained by a variety of different factors including the loss of innervation from alpha‐motor neurons 107, reduced dietary protein intake 108, 109, and less physical activity 110. Individuals with lower muscle mass have more difficulty in performing ADL and IADL 111, 112. Furthermore, it has been suggested that the infiltration of fat into the muscle is a risk factor for low muscle mass, which is associated with worsening ADL and IADL 111. Prior studies exploring the effect of training on muscle mass demonstrate its effectiveness in increasing performance and preservation of ADL and IADL 113, 114. Muscle mass has also been shown to improve in response to resistance exercise training and nutritional interventions, even in frail populations 109, 113, 115, 116, 117.

Muscle strength

The predictive ability of muscle strength at baseline of ADL and IADL decline is consistent with a previous study consisting of 6089 participants, which suggested that having higher muscle strength was protective against the onset of future disability.80 However, the discrepancies in measures and cut‐offs and thus a lack of consensus in measuring muscle strength. Handgrip strength has been used as a measure of upper limb strength in older populations.80, 118 However handgrip strength should not be used as an approximation of overall muscle strength in older adults because of the variation between individuals and the variation in muscle groups within the same individual 119. Although a strong association between muscle mass and muscle strength exists 120, 121, 122, muscle strength may better predict worsening ADL and IADL as muscle mass can also be influenced by factors like disease, muscle use, and muscle morphology 123. It has previously been hypothesized that there is a minimal amount of muscle strength required to complete ADL 124. Handgrip strength declines by 0.06 kg per year up to the age of 50 with an even steeper decline of 0.37 kg per year after the age of 50 years 125. In healthy older adults, large changes in muscle strength have little effect on ADL while small changes in a frail population have a more profound effect 124. This suggests that the completion of ADL and IADL requires a minimum threshold of strength and that higher muscle strength provides individuals with a protective reserve against the development of ADL and IADL dependence.14 Thus, individuals with lower muscle strength, and therefore a lower protective reserve, are at higher risk of developing new ADL and IADL dependence at follow‐up.14 The prevalence of ADL and IADL dependence increases with age, muscle strength amongst older adults has been shown to decrease.126, 127, 128, 129 Gender has also been suggested to influence muscle strength as hospitalized older adults demonstrated an association between handgrip strength with ADL and IADL in male patients, but not female patients 112. Individuals with high muscle strength at baseline are also likely to preserve their higher handgrip strength at follow‐up 129. It would be expected that the association is stronger with longer follow‐up duration. However, this was not observed in our meta‐analysis. A reason this could be due to the different baseline ages and follow‐up duration between studies. Given that muscle mass decreases at a slower rate compared with muscle strength, it may be easier to preserve and maintain muscle mass, which can also prevent the decline in muscle strength.130 Muscle quality, which refers to the muscle strength or power per unit of muscle mass,131 has been associated with worse ADL in a previous cross‐sectional study.10 As previous studies support the assumption that muscle strength decline occurs faster than muscle mass, it also suggests that muscle quality has likewise declined 130. Physical performance measured by gait speed has previously shown that a higher gait speed to be associated with higher muscle quality in older adults 132, 133. Currently, no studies have explored the association between muscle quality and worsening ADLs; however, as muscle quality has been shown to decline with age 134, 135, 136, it can be expected to observe similar results as muscle mass, strength, and physical performance.

Physical performance

Lower SPPB scores were associated with worsening ADL at follow‐up. The SPPB encompasses three assessments that require strength, balance, dexterity, and cognitive control, which captures functional elements that are required for the completion of ADL and IADL 137, 138, 139. Lower extremity physical performance measured by the SPPB was associated with worse ADL. Furthermore, a difference in score of 1 point on the SPPB was also significantly associated with worse ADLs as shown in this review and prior research 138. Lower SPPB scores are a reflection of impaired skeletal muscle function and structural changes associated with chronic inflammatory processes 140, as well as neurological pathologies that impair gait and balance 141 that are thought to mediate the development of ADL and IADL dependence 142. High heterogeneity was observed between studies that evaluated the SPPB as a continuous variable compared with a dichotomous variable (low vs. high). The findings from this review were consistent with a previous systematic review, where the SPPB was predictive of long‐term disability.143 Gait speed measured by a 4 m walk test is a component of the SPPB and is often used in clinical settings to identify individuals at high risk of adverse health outcomes144 and assist in the diagnosis of sarcopenia.145 Gait speed is both a simple and highly reproducible measure of physical performance and is comparable with the SPPB as a predictor of ADL dependence.56, 146 In community‐dwelling outpatients, the association between gait sped with ADL and IADL was stronger than its association with the other sarcopenia diagnosis criteria.147 While having a higher 0.1 m/s gait speed was not statistically significant in this study, all other analyses showed a lower gait speed favoured a worsening ADL and/or IADL. One study, which evaluated 27 200 community‐dwelling older adults for gait speed, demonstrated its predictive value on the development of disability.148 Other studies reported different cut‐offs for slow and fast gait speed, but no single threshold was evident with the incidence of disability.148 Therapies or preventative interventions targeted at improving or maintaining gait speed should be considered amongst older adults, as these changes are reflective of the progression and development of ADL and IADL dependence.149, 150 The findings of this meta‐analysis also resonate with a previous systematic review, which demonstrated that slow gait speed was associated with worsening ADL in older populations.15, 151 One leg balance was significantly associated with worsening ADL in the follow‐up. The importance of balance is well described controlling both static and dynamic posture while performing a variety of daily activities,152, 153 such that it has been used as a predictor of high‐risk individuals prone to falls.154 Although one previous study reported no statistically significant association between one leg balance and ADL dependence, the three studies included in this meta‐analysis demonstrated a strong association between low one leg balance time and worsening ADLs.155 Timed up and go is a measure of walking, balance, strength, and cognition.156 A descriptive meta‐analysis exploring the cut‐off times of the timed up and go test reported cut‐off values of 8.1, 9.2, and 11.3 s for those aged 60–69, 70–79, and 80–99 years old, respectively.157 All studies included in the meta‐analysis84, 89, 91 had greater cut‐offs for a slow timed up and go time, potentially underestimating the pooled effect size. Timed up and go had a smaller effect size but less heterogeneity in predicting worsening ADLs compared with one leg balance in this meta‐analysis. Prior research comparing different measures of balance reported timed up and go as being a better predictor of ADL in older the community‐dwelling population.158 The chair stand test was significantly associated with worsening ADL but not IADL. Chair stand test has been used as a measure of lower body strength in older adults in community‐dwelling older adults and as part of the SPPB.11, 159 A previous study reported that 22% of community‐dwelling older individuals are unable to complete the chair stand test (5 to 10 rises) without the use of hands and/or arms.11 The 30 s chair stand test may be a better protocol as it is more reliable given that some individuals are unable to complete standard protocols and the floor effect.159 Surprisingly, no studies included in the meta‐analysis reported the 30 s protocol; only the 5× chair stand test was used. High heterogeneity was observed in IADL perhaps because of the different cut‐off points used (11.2 s103 and 13 s160) although this was not the case for ADLs.

Strength and limitations

This systematic review and meta‐analysis explored muscle mass, muscle strength, and physical performance as predictors for ADL and IADL rather than limiting to just a single measure. By evaluating the effects of all three measures, this review presented the most detailed assessment of this topic. To reduce the risk of reverse causation when interpreting the associations reported, only prospective studies were included. There are also limitations to this review. Not all studies were pooled into a meta‐analysis because of differences in measures and cut‐offs of muscle mass, muscle strength, and physical performance, the use of different statistical analyses, or the lack of data required to calculate an OR. Studies that were pooled were also reporting univariate and multivariate analyses, adjusting for different confounders that were inconsistent between studies that may have further led to an over or under estimation of the effect sizes. Studies that did not have a primary aim of exploring the association between baseline muscle measures with ADL and/or IADL may have used less standardized procedures. The follow‐up duration between studies varied significantly, which may have impacted the results.

Future recommendations

There were few pre‐existing studies that explored the association between baseline muscle mass and ADL and/or IADL. Studies should continue to investigate the association of muscle mass alone with ADL and/or IADL. Future studies should also explore the association of muscle quality with ADL and/or IADL. Interventions tailored for specifically increasing muscle measures should be developed to prevent individuals from having worsening ADL and/or IADL in their future. Interventions should be developed with the focus of preserving or increasing muscle measures as we age.

Conclusions

This study quantified the current research available between muscle measures and (I)ADL. Muscle mass is predictive of ADL and IADL decline whereas muscle strength and physical performance are predictive of both ADL and/or IADL decline. Future studies should continue to develop and improve interventions to preserve and improve muscle measures to prevent ADL and IADL dependence.

Conflict of Interest

Daniel X. M. Wang, Jessica Yao, Yasar Zirek, Esmee M. Reijnierse, and Andrea B. Maier declare that they have no conflict of interest. Table S1. Search Strategy Click here for additional data file. Data S2. Newcastle–Ottawa Scale Click here for additional data file. Table S3. Breakdown of the ADL components in articles that created their own questionnaire Click here for additional data file.
  151 in total

1.  Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery.

Authors:  J M Guralnik; L Ferrucci; C F Pieper; S G Leveille; K S Markides; G V Ostir; S Studenski; L F Berkman; R B Wallace
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2000-04       Impact factor: 6.053

2.  Ability of fat and fat-free mass percentages to predict functional disability in older men and women.

Authors:  J Broadwin; D Goodman-Gruen; D Slymen
Journal:  J Am Geriatr Soc       Date:  2001-12       Impact factor: 5.562

3.  Loss of muscle strength, mass (sarcopenia), and quality (specific force) and its relationship with functional limitation and physical disability: the Concord Health and Ageing in Men Project.

Authors:  Noran N Hairi; Robert G Cumming; Vasi Naganathan; David J Handelsman; David G Le Couteur; Helen Creasey; Louise M Waite; Markus J Seibel; Philip N Sambrook
Journal:  J Am Geriatr Soc       Date:  2010-11       Impact factor: 5.562

4.  Clusters of functional domains to identify older persons at risk of disability.

Authors:  Luisa Costanzo; Claudio Pedone; Matteo Cesari; Luigi Ferrucci; Stefania Bandinelli; Raffaele Antonelli Incalzi
Journal:  Geriatr Gerontol Int       Date:  2017-12-28       Impact factor: 2.730

5.  Assessing risk for the onset of functional dependence among older adults: the role of physical performance.

Authors:  T M Gill; C S Williams; M E Tinetti
Journal:  J Am Geriatr Soc       Date:  1995-06       Impact factor: 5.562

Review 6.  The statistical basis of meta-analysis.

Authors:  J L Fleiss
Journal:  Stat Methods Med Res       Date:  1993       Impact factor: 3.021

7.  Sarcopenia-related parameters and incident disability in older persons: results from the "invecchiare in Chianti" study.

Authors:  Matteo Cesari; Yves Rolland; Gabor Abellan Van Kan; Stefania Bandinelli; Bruno Vellas; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2014-10-15       Impact factor: 6.053

8.  Muscle strength and physical performance as predictors of mortality, hospitalization, and disability in the oldest old.

Authors:  Delphine Legrand; Bert Vaes; Catharina Matheï; Wim Adriaensen; Gijs Van Pottelbergh; Jean-Marie Degryse
Journal:  J Am Geriatr Soc       Date:  2014-05-06       Impact factor: 5.562

9.  Comparison of quadriceps strength and handgrip strength in their association with health outcomes in older adults in primary care.

Authors:  On Ying A Chan; Anne H van Houwelingen; Jacobijn Gussekloo; Jeanet W Blom; Wendy P J den Elzen
Journal:  Age (Dordr)       Date:  2014-10-04

10.  Loss of independence in activities of daily living in older adults hospitalized with medical illnesses: increased vulnerability with age.

Authors:  Kenneth E Covinsky; Robert M Palmer; Richard H Fortinsky; Steven R Counsell; Anita L Stewart; Denise Kresevic; Christopher J Burant; C Seth Landefeld
Journal:  J Am Geriatr Soc       Date:  2003-04       Impact factor: 5.562

View more
  74 in total

1.  Body mass index affects postoperative daily activities of older patients after gastrectomy.

Authors:  Tatsuro Inoue; Hidetaka Wakabayashi; Keisuke Maeda; Ryo Momosaki
Journal:  Eur Geriatr Med       Date:  2021-02-15       Impact factor: 1.710

2.  Health-related physical indicators and self-rated quality of life in older adults with neurocognitive disorder.

Authors:  Flávia Borges-Machado; Duarte Barros; Laetitia Teixeira; Óscar Ribeiro; Joana Carvalho
Journal:  Qual Life Res       Date:  2021-03-28       Impact factor: 4.147

3.  Association between dietary inflammatory index score and muscle mass and strength in older adults: a study from National Health and Nutrition Examination Survey (NHANES) 1999-2002.

Authors:  Jingjing Ming; Lingzhi Chen; Tianyi Chen; James R Hébert; Peng Sun; Li Zhang; Hongya Wang; Qingkuo Wu; Cancan Zhang; Nitin Shivappa; Bo Ban
Journal:  Eur J Nutr       Date:  2022-07-09       Impact factor: 5.614

4.  JCSM: growing together with cachexia and sarcopenia research.

Authors:  Ann-Kathrin Fröhlich; Monika Diek; Corinna Denecke; Stephan von Haehling; Sara Hadzibegovic; Markus S Anker
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-12       Impact factor: 12.910

5.  Muscle Evaluation and Hospital-Associated Disability in Acute Hospitalized Older Adults.

Authors:  M Nagae; H Umegaki; A Yoshiko; K Fujita; H Komiya; K Watanabe; Y Yamada; T Sakai
Journal:  J Nutr Health Aging       Date:  2022       Impact factor: 5.285

6.  Cross-sectional and prospective association between personality traits and IADL/ADL limitations.

Authors:  Brice Canada; Yannick Stephan; Hervé Fundenberger; Angelina R Sutin; Antonio Terracciano
Journal:  Psychol Aging       Date:  2021-03-11

7.  Skeletal Muscle Mass and Higher-Level Functional Capacity in Female Community-Dwelling Older Adults.

Authors:  Shuichi Wakayama; Yoshihiko Fujita; Keisuke Fujii; Takeshi Sasaki; Hiroshi Yuine; Kazushi Hotta
Journal:  Int J Environ Res Public Health       Date:  2021-06-22       Impact factor: 3.390

8.  Three definitions of probable sarcopenia and associations with falls and functional disability among community-dwelling older adults.

Authors:  Juliana Carvalho Segato Marincolo; Ivan Aprahamian; Ligiana Pires Corona; Anita Liberalesso Neri; Mônica Sanches Yassuda; Flávia Silva Arbex Borim
Journal:  Osteoporos Sarcopenia       Date:  2021-05-25

9.  Relationship between Oral Hypofunction and Sarcopenia in Community-Dwelling Older Adults: The Otassha Study.

Authors:  Yoshihiro Kugimiya; Masanori Iwasaki; Yuki Ohara; Keiko Motokawa; Ayako Edahiro; Maki Shirobe; Yutaka Watanabe; Shuichi Obuchi; Hisashi Kawai; Yoshinori Fujiwara; Kazushige Ihara; Hunkyung Kim; Takayuki Ueda; Hirohiko Hirano
Journal:  Int J Environ Res Public Health       Date:  2021-06-21       Impact factor: 3.390

10.  Phase Angle Is a Marker of Muscle Quantity and Strength in Overweight/Obese Former Athletes.

Authors:  Catarina N Matias; Francesco Campa; Catarina L Nunes; Rubén Francisco; Filipe Jesus; Miguel Cardoso; Maria J Valamatos; Pedro Mil Homens; Luís B Sardinha; Paulo Martins; Cláudia Minderico; Analiza M Silva
Journal:  Int J Environ Res Public Health       Date:  2021-06-21       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.